Pacifici R, Rifas L, McCracken R, Avioli L V
Division of Endocrinology and Metabolism, Jewish Hospital of St. Louis, Missouri 63110.
Exp Gerontol. 1990;25(3-4):309-16. doi: 10.1016/0531-5565(90)90067-c.
Interleukin-1 (IL-1), a cytokine best known for its ability to stimulate lymphocyte proliferation, has recently been shown to stimulate bone resorption and modulate bone formation in vivo. Consequently, the authors have devised a series of studies to investigate the relationship between bone remodeling, menopause, and monocyte IL-1-secretion. In a first study, monocytes from osteoporotic patients were found to produce more IL-1 than monocytes from control subjects. IL-1 activity was also found to reflect histomorphometric indices of bone formation, but not of bone resorption. In a second study, devised to assess the effect of menopause on the relationship between IL-1 and bone turnover, a significant correlation was found between IL-1 and BGP in premenopausal osteoporotic women and osteoporotic men, but not in both postmenopausal osteoporotic subjects and normal subjects of either sex. In a third study, IL-1 from untreated postmenopausal women was found to be higher than in either untreated premenopausal or estrogen/progesterone-treated postmenopausal women. A significant negative correlation was found between IL-1 and years since menopause in both the healthy and osteoporotic postmenopausal women. Premenopausal IL-1 levels were achieved within eight years of menopause in the healthy but not in the osteoporotic subjects. In osteoporotic women, high IL-1 levels were evident as long as 15 years after menopause. IL-1 also correlated inversely with mineral density as measured by quantitative computer tomography. In prospective study, treatment with estrogen/progesterone caused a significant increase in IL-1 activity. This data indicates that monocyte IL-1 production mirrors the rate of bone turnover in both the healthy and osteoporotic patient, and that alteration in IL-1 production may underlie the postmenopausal acceleration of bone loss and its inhibition by ovarian steroids.
白细胞介素-1（IL-1）是一种以刺激淋巴细胞增殖能力而闻名的细胞因子，最近已被证明能在体内刺激骨吸收并调节骨形成。因此，作者设计了一系列研究来调查骨重塑、绝经和单核细胞IL-1分泌之间的关系。在第一项研究中，发现骨质疏松患者的单核细胞比对照组受试者的单核细胞产生更多的IL-1。还发现IL-1活性反映了骨形成的组织形态计量学指标，但不反映骨吸收的指标。在第二项旨在评估绝经对IL-1与骨转换关系影响的研究中，发现绝经前骨质疏松女性和骨质疏松男性的IL-1与骨钙素之间存在显著相关性，但绝经后骨质疏松受试者和任何性别的正常受试者中均未发现这种相关性。在第三项研究中，发现未治疗的绝经后女性的IL-1高于未治疗的绝经前女性或接受雌激素/孕激素治疗的绝经后女性。在健康和骨质疏松的绝经后女性中，均发现IL-1与绝经后的年限之间存在显著负相关。健康女性在绝经后八年内达到绝经前的IL-1水平，而骨质疏松患者则未达到。在骨质疏松女性中，绝经后长达15年都有明显的高IL-1水平。IL-1也与通过定量计算机断层扫描测量的矿物质密度呈负相关。在前瞻性研究中，雌激素/孕激素治疗导致IL-1活性显著增加。这些数据表明，单核细胞IL-1的产生反映了健康和骨质疏松患者的骨转换率，并且IL-1产生的改变可能是绝经后骨丢失加速及其受卵巢类固醇抑制的基础。
